12/16
08:30 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Evercore ISI from $7.00 to $5.00. They now have an "outperform" rating on the stock.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Evercore ISI from $7.00 to $5.00. They now have an "outperform" rating on the stock.
12/16
07:05 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.
12/13
12:42 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Royal Bank of Canada from $5.00 to $4.00. They now have a "sector perform" rating on the stock.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Royal Bank of Canada from $5.00 to $4.00. They now have a "sector perform" rating on the stock.
12/13
10:19 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Barclays PLC from $5.00 to $3.00. They now have an "equal weight" rating on the stock.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Barclays PLC from $5.00 to $3.00. They now have an "equal weight" rating on the stock.
12/13
09:03 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its "neutral" rating re-affirmed by analysts at Chardan Capital.
High
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its "neutral" rating re-affirmed by analysts at Chardan Capital.
12/13
08:05 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Robert W. Baird from $10.00 to $8.00. They now have an "outperform" rating on the stock.
High
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Robert W. Baird from $10.00 to $8.00. They now have an "outperform" rating on the stock.
12/13
07:40 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $3.00 price target on the stock, down previously from $11.00.
High
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $3.00 price target on the stock, down previously from $11.00.
12/13
07:40 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Truist Financial Co. from a "buy" rating to a "hold" rating.
High
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Truist Financial Co. from a "buy" rating to a "hold" rating.
12/12
04:00 pm
edit
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
High
Report
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
12/11
08:08 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $4.00 price target on the stock, down previously from $7.00.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $4.00 price target on the stock, down previously from $7.00.
12/10
01:09 pm
edit
Editas Stock Rises on Updated Data From SCD Study of Reni-Cel [Yahoo! Finance]
Neutral
Report
Editas Stock Rises on Updated Data From SCD Study of Reni-Cel [Yahoo! Finance]
12/9
12:00 pm
edit
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
Low
Report
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
12/4
01:28 pm
edit
Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report? [Yahoo! Finance]
11/25
08:02 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Bank of America Co. from a "buy" rating to an "underperform" rating. They now have a $1.00 price target on the stock, down previously from $13.00.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Bank of America Co. from a "buy" rating to an "underperform" rating. They now have a $1.00 price target on the stock, down previously from $13.00.
11/6
01:02 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.
11/6
09:00 am
edit
Editas Medicine to Participate in Upcoming Investor Conferences
Low
Report
Editas Medicine to Participate in Upcoming Investor Conferences
11/6
07:21 am
edit
Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19% [Yahoo! Finance]
Medium
Report
Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19% [Yahoo! Finance]
11/5
05:34 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
11/5
01:04 pm
edit
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y [Yahoo! Finance]
Low
Report
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y [Yahoo! Finance]
11/5
11:36 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Royal Bank of Canada from $8.00 to $5.00. They now have a "sector perform" rating on the stock.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Royal Bank of Canada from $8.00 to $5.00. They now have a "sector perform" rating on the stock.
11/5
11:19 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Stifel Nicolaus from $17.00 to $11.00. They now have a "buy" rating on the stock.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Stifel Nicolaus from $17.00 to $11.00. They now have a "buy" rating on the stock.
11/5
10:41 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Wells Fargo & Company from $9.00 to $7.00. They now have an "overweight" rating on the stock.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Wells Fargo & Company from $9.00 to $7.00. They now have an "overweight" rating on the stock.
11/5
10:40 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Truist Financial Co. from $12.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Truist Financial Co. from $12.00 to $8.00. They now have a "buy" rating on the stock.
11/5
09:43 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Barclays PLC from $7.00 to $5.00. They now have an "equal weight" rating on the stock.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Barclays PLC from $7.00 to $5.00. They now have an "equal weight" rating on the stock.
11/4
01:15 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.